Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

Y0000750

Dorzolamide for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Dorzolamide hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill) :
C10H16N2O4S3 · HCl
Numéro CAS:
130693-82-2
Poids moléculaire :
360.90
Beilstein:
5896026
Numéro MDL:
MFCD00884659
Code UNSPSC :
41116107
ID de substance PubChem :
329831128
Nomenclature NACRES :
NA.24
Le tarif et la disponibilité ne sont pas disponibles actuellement.

Qualité

pharmaceutical primary standard

Famille d'API

dorzolamide

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

Cl.CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O

InChI

1S/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1

Clé InChI

OSRUSFPMRGDLAG-QMGYSKNISA-N

Informations sur le gène

human ... CA2(760)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dorzolamide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000726

Dorzolamide hydrochloride, European Pharmacopoeia (EP) Reference Standard

1225281

Dorzolamide hydrochloride, United States Pharmacopeia (USP) Reference Standard

Y0000727

Dorzolamide Impurity A, European Pharmacopoeia (EP) Reference Standard

1225292

Dorzolamide hydrochloride Related Compound A, United States Pharmacopeia (USP) Reference Standard

1225306

Dorzolamide Related Compound D, United States Pharmacopeia (USP) Reference Standard

BP1069

Dorzolamide hydrochloride, British Pharmacopoeia (BP) Reference Standard

PHR1925

Dorzolamide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

BP1071

Dorzolamide impurity D, British Pharmacopoeia (BP) Reference Standard

BP1070

Dorzolamide impurity B, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H373

Classification des risques

Acute Tox. 4 Oral - STOT RE 2

Organes cibles

Central nervous system,Gastrointestinal tract,Bone,Blood,Bladder

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Mohamed A Genead et al.
Retina (Philadelphia, Pa.), 32(4), 826-833 (2011-09-03)
: To determine the value of a topical carbonic anhydrase inhibitor on the macular thickness and function in choroideremia patients with cystoid macular edema. : Two choroideremia patients with cystoid macular edema, observed by spectral-domain optical coherence tomography, were treated
Aukje van Gestel et al.
Acta ophthalmologica, 90(1), 20-31 (2012-02-01)
To evaluate the long-term effects and costs of four treatment strategies for primary open-angle glaucoma compared to usual care. Cost-effectiveness analyses with a lifelong horizon were made from a societal perspective. Data were generated with a patient-level model based on
Mumin Hakan Eren et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 28(4), 381-386 (2012-02-11)
To compare the efficacy and safety of dorzolamide hydrochloride 2%/timolol maleate 0.5% fixed combination (DTFC) with latanoprost 0.005%/timolol maleate 0.5% fixed combination (LTFC) on diurnal intraocular pressure (IOP) in patients with primary open-angle glaucoma. Thirty-three primary open-angle glaucoma patients with
Kelly J Sigle et al.
Veterinary ophthalmology, 14 Suppl 1, 48-53 (2011-09-23)
To determine the extent of fluctuation in circadian intraocular pressure (IOP) and the efficacy of topical dorzolamide 2% q 8 h in lowering IOP and blunting circadian fluctuation in IOP in glaucomatous cats. Seven adult cats with primary congenital glaucoma
Yasuhiro Ikeda et al.
The British journal of ophthalmology, 97(9), 1187-1191 (2013-06-21)
To evaluate the therapeutic effect of continuous treatment with topical dorzolamide (a carbonic anhydrase inhibitor) for cystoid macular oedema (CME) associated with retinitis pigmentosa (RP). 18 eyes in 10 patients with CME secondary to RP were included. Baseline visual acuity
Afficher tous les articles scientifiques apparentés

Questions

Évaluations

Aucune valeur de notation

Filtres actifs

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique